Overactive bladder syndrome: Is a request for a dose increase indicative of more severe symptoms? Results from a randomised, double-blind, placebo-controlled, risfng-dose study of solifenacin (SUNRISE)

Authors
Cardozo L. , Avdoshin V. , Wolski Z. , Pavlik I. , Sofras F.E. , Toth Z. , Vasco P.M. , Drogendijk T. , Wright D.M. , Bolodeoku J.
Conference proceedings
INTERNATIONAL UROGYNECOLOGY JOURNAL
Publisher
SPRINGER LONDON LTD
Language
English
Status
Published
Volume
18
Year
2007
Date of creation
19.10.2018
Date of change
19.10.2018
Short link
https://repository.rudn.ru/en/records/article/record/8759/
Share

Other records